Assessment of the cost-effectiveness of Australia's risk-sharing agreement for direct-acting antiviral treatments for hepatitis C: a modelling study

• Main Authors: Dr Nick Scott (Author), Ms Anna Palmer (Author), Mr Tom Tidhar (Author), Prof Mark Stoove (Author), Dr Rachel Sacks-Davis (Author), A/Prof Joseph S. Doyle (Author), Dr Alisa Pedrana (Author), Prof Alexander J. Thompson (Author), Prof David P. Wilson (Author), Prof Margaret Hellard (Author)
• פורמט: ספר
• יצא לאור: Elsevier, 2022-01-01T00:00:00Z.
• נושאים: article
• גישה מקוונת: Connect to this object online.

Summary: Background: Hepatitis C elimination may be possible with broad uptake of direct-acting antiviral treatments (DAAs). In 2016 the Australian government committed A$1.2 billion for five years of unlimited DAAs (March 2016 to February 2021) in a risk-sharing agreement with pharmaceutical compan...